On November 3, 2022 ATCC, the world’s premier biological materials management and standards organization, reported a new line of products, CAR-T Target luciferase reporter cell lines, that will support immuno-oncology (IO) discovery and development of novel immunotherapies (Press release, American Type Culture Collection (ATCC), NOV 3, 2022, View Source [SID1234623024]). These models have a high endogenous expression of relevant chimeric antigen receptor (CAR)-T target antigens such as HER2, CD19, and CD20. These new IO tools are comprised of both hematological cancer and solid tumor cell lines that express a luciferase reporter.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"At ATCC, our mission is to offer the scientific community credible biological products that support incredible achievements in basic science, drug discovery, translational medicine and public health," said Raymond H. Cypess, D.V.M., Ph.D., chairman and CEO of ATCC. "We believe that these innovative CAR-T target cell lines will help mitigate some of the formidable roadblocks that IO researchers encounter in their fight against cancer."

These new IO tools alleviate many of the challenges in evaluating the ex vivo biofunction of CAR-T cells. Coming from highly authenticated and characterized human ATCC cell lines eliminates questions of cell provenance, as well as potential donor-to-donor and cross-species issues. In addition, these lines stably express a sensitive, robust, and easy-to-use reporter system and have been shown in a recent study to display dose-dependent targeting.

"As IO is one of the fastest growing sectors in cancer research and therapeutics, ATCC continues to prioritize the development of solutions to support the global effort in advancing this field," said Fang Tian, Ph.D., Director of Biological Content.

ATCC supports cancer research and drug discovery with thousands of human and animal cancer cell lines for a better understanding of tumor biology, cancer genomics, tumor biomarkers, and advancing novel therapeutics. In addition to providing the most commonly used historical tumor cell lines, ATCC develops genetically engineered cell lines, tumor organoids, reporter cell lines, and drug-resistant cell lines for the global scientific community.

ATCC will be showcasing its immuno-oncology research tools at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 2022 Annual Meeting in Boston, Massachusetts, November 8 through November 12, 2022. At booth 313, they will present the poster, "Luciferase reporter cancer cell lines facilitate CAR-T development."

On November 3, 2022 Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, reported that members of its executive team will participate in the following upcoming investor conferences (Press release, Aura Biosciences, NOV 3, 2022, View Source [SID1234623023]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Stifel 2022 Healthcare Conference at the Lotte New York Palace on Wednesday, November 16, 2022.
Presentation at 10:55 a.m. ET.
5th Annual 2022 Evercore ISI HealthCONx on Tuesday, November 29, 2022.
Fireside chat at 8:25 a.m. ET.
A live webcast of the Stifel presentation and Evercore ISI fireside chat will be available on the "Investors & Media" page under the "Events & Presentations" section of the Company’s website at View Source, where a replay of the webcasts will be archived for 90 days following the presentation date.

On November 3, 2022 Pyramid Biosciences, Inc., a privately-held, clinical-stage biotechnology company focused on developing new and highly differentiated precision therapies for cancer and other serious diseases, reported that Chief Executive Officer, Brian Lestini, M.D., Ph.D., will present at the 2022 Jefferies London Healthcare Conference on Thursday, November 17, 2022 at 2:40 PM GMT (Press release, Pyramid Biosciences, NOV 3, 2022, View Source [SID1234623022]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be accessible on Pyramid’s website at Jefferies audiocast link or by visiting: View Source A replay of the call will be archived for 90 days after the call.

For more information on the conference or to schedule a one-on-one meeting with the Pyramid Biosciences management, please contact your Jefferies representative.

On November 3, 2022 CivaTech Oncology Inc., reported CivaSheet significantly boosts outcomes for borderline resectable and locally advanced pancreatic cancer patients (Press release, CivaTech Oncology, NOV 3, 2022, View Source [SID1234623021]). CivaSheet, an implantable, targeted, shielded radiation device delivers an aggressive dose immediately to the pancreas region following surgical resection. Studies have been conducted in multi-institutional settings, garnering support from the NIH/NCI and SBIR programs. This is the first analysis of outcomes from one of the participating institutions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Between 2017-2020, 19 patients received 3-6 months of chemotherapy, radiation (either conventionally fractionated or SBRT) followed by surgery with CivaSheet placement, mostly prospectively on the Phase 1/2 clinical trial (CivaTech Oncology). During the same time period, data were collected for 16 patients matched by demographics, tumor and treatment factors, who did not have CivaSheet placed.

Patients followed in this evaluation were all treated at Virginia Commonwealth University(VCU), Massey Cancer Center, and were followed until date of death or last follow up and assessed for local control, disease-free survival, cause-specific survival and overall survival.

Cox proportional hazards models indicated that treatment with CivaSheet was associated with substantially longer disease-free survival. As shown at the right, approximately 50% of CivaSheet patients survived 2 years without recurrence and at least 30% of patients were alive without recurrence at almost 5 years. In contrast, no non-CivaSheet patients survived two years without recurrence or death from disease.

"These data are strongly compelling and demonstrate significant impact on the increased survival of pancreatic cancer patients," commented Suzanne Babcock, Chairman of CivaTech Oncology. Patients have no device related toxicity and report a better quality of life without having disease recurrence and subsequent treatment.

VCU radiation oncologist, Emma Fields MD, is excited by these results and noted "many of my patients who had CivaSheet placed are alive and disease free in long term follow up. I think this is very exciting and can offer hope to our patients."

On November 3, 2022 IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on the creation and development of IgM antibodies, and ADC Therapeutics SA (NYSE:ADCT) reported that they have signed a collaboration and supply agreement to evaluate the combination of imvotamab, the novel bispecific IgM antibody, engaging T cells and targeting CD20 and CD3 proteins, d ‘IGM, and ZYNLONTA (loncastuximab tesirine-lpyl), CD19-targeting antibody-drug conjugate (ADC) from ADC Therapeutics, for the treatment of patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL) ( R/R) (Press release, IGM Biosciences, NOV 3, 2022, View Source [SID1234623020]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

" Patients with B-cell non-Hodgkin’s lymphoma (NHL) need effective and well-tolerated treatments," said Chris Takimoto, MD, Ph.D., FACP, Chief Medical Officer at IGM Biosciences. " We welcome this collaboration with ADC Therapeutics to provide a novel combination therapy targeting both CD19 and CD20 expressing cells for patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL). We look forward to working with the ADC Therapeutics team and starting the clinical trial in the first quarter of 2023."

According to data presented at the 2021 American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting, imvotamab indicated 50% complete response (CR) at the likely optimal dose of 100 mg (n=10). Among the 28 patients treated in the current dose-adjusted cohorts, cytokine release syndrome was observed in <20% of patients.

" We are excited to collaborate with IGM Biosciences to explore ZYNLONTA in combination with imvotamab," said Joseph Camardo, MD, Chief Medical Officer of ADC Therapeutics. " This collaboration extends ADC Therapeutics’ commitment to maximizing the potential of our CD19-targeting ADC for patients with significant unmet medical needs, both as a single agent and in novel combinations with other anti-cancer agents. The safety profile of imvotamab and the activity observed so far in phase 1 are promising for future development. »

Under the terms of the agreement, IGM will be responsible for conducting the clinical trial to evaluate the safety and efficacy of imvotamab in combination with ZYNLONTA in the treatment of patients with R/R NHL. ADC Therapeutics will provide clinical expertise regarding ZYNLONTA and supply the drug for the trial. IGM expects to start the trial in the first quarter of 2023. The clinical collaboration is based on compelling mechanistic analysis and preclinical data showing activity of this approach.